Evidence map›Paper›PMID 41139985›Full record

Trial reportBritish journal of haematology2026

Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial.

Khaled M Musallam, Ali T Taher, John B Porter, Antonis Kattamis, Mrudula B Glassberg, Luciana Moro Bueno, Patricia Martin-Regueira, Marta Reverte, Loyse Felber Medlin, Matthew Dyer and 2 more

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Khaled M MusallamCenter for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Medical City, Abu Dhabi, United Arab Emirates.ORCID https://orcid.org/0000-0003-3935-903X
Ali T TaherDepartment of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
John B PorterUniversity College London, University College London Hospitals, London, UK.
Antonis KattamisFirst Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.
Mrudula B GlassbergBristol Myers Squibb, Princeton, New Jersey, USA.
Luciana Moro BuenoCelgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Patricia Martin-RegueiraCelgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Marta ReverteCelgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Loyse Felber MedlinCelgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Matthew DyerFormerly Bristol Myers Squibb, Uxbridge, UK.
Kefeng WangBristol Myers Squibb, Princeton, New Jersey, USA.
Maria Domenica CappelliniFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Medicina ad Indirizzo Metabolico, Milan, Italy.

Funding

AcceleronBristol-Myers Squibb
6 · The paper itself

Abstract

In this post hoc analysis of the phase 2 BEYOND trial, the majority of patients with non-transfusion-dependent β-thalassaemia achieved clinically meaningful haemoglobin levels ≥10.0 g/dL and increases from baseline ≥1.0 g/dL, thresholds associated with reduced risk of morbidity and mortality and recommended as an indication and target for treatment by international management guidelines, respectively.

Indexed as

Activin Receptors, Type IIbeta-ThalassemiaHemoglobinsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultActivin Receptors, Type IIHemoglobinsImmunoglobulin Fc FragmentsluspaterceptRecombinant Fusion Proteinsanaemiaclinical trialshaemoglobinβ‐thalassaemia

Identifiers

PMID41139985
PMCPMC12819085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.